GlassScriptPhysician profile
Dana Ondrias
NPI 1871598060
$19,013.77
in general payments reported to CMS, 2019-2025
25 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,776 · 2020: $2,909 · 2021: $1,817 · 2022: $2,595 · 2023: $1,383 · 2024: $2,602 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,934 · Consulting Fee: $1,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,934.23 |
| Consulting Fee | $1,982.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $12,685.15 | 2019-2025 | Wavelight Refractive Suite, Wavelight Ex500 Excimer Laser, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $2,281.73 | 2019-2025 | Tecnis Iol |
| Carl Zeiss Meditec USA, INC. | $784.49 | 2021-2025 | Cirrus Hd-Oct |
| Sun Pharmaceutical Industries INC. | $709.71 | 2019-2025 | Cequa |
| Abbvie INC. | $375.94 | 2022-2024 | |
| Carl Zeiss Meditec Cataract Technology INC. | $368.37 | 2020-2023 | |
| Allergan, INC. | $280.86 | 2019-2022 | |
| Dompe US, INC. | $248.81 | 2019-2025 | Oxervate |
| Oyster Point Pharma, INC. | $218.02 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $156.83 | 2019-2025 | |
| Biotissue Holdings INC. | $150.62 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $126.45 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Shire North American Group INC | $104.10 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $96.63 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $88.39 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $64.30 | 2025 | Vevye |
| Astellas Pharma US INC | $58.09 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $37.24 | 2019-2020 | |
| Eyevance Pharmaceuticals LLC | $35.97 | 2019 | |
| Amgen INC. | $34.13 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $22.92 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.30 | 2019 | |
| Topcon Healthcare Solutions, INC. | $21.44 | 2019 | |
| Kala Pharmaceuticals, INC. | $21.36 | 2021 | |
| Sight Sciences, INC. | $19.92 | 2025 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Ondrias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.